eureKARE launches with $60 million to construct and finance subsequent technology biotech firms in Europe
$60 million Sequence A capital to finance and construct disruptive European biotechnology firms in two cutting-edge fields of analysis: the microbiome and artificial biology
Biotech start-up studio mannequin to pick and nurture top quality European innovation with revolutionary potential to maximise alternatives for traders and scientists for the advantage of sufferers
eureKARE is guided by influential founder, Alexandre Mouradian, accompanied by a highly expert staff and an worldwide Scientific Advisory Board of famend consultants
Paris, France – 18 Might 2021: eureKARE (“the Firm”), a pioneering new firm centered on financing and constructing subsequent technology biotechnology firms within the disruptive fields of the microbiome and artificial biology, at present publicizes its launch with a $60 million Sequence A financing. The financing was supported by high-net price traders and household workplaces.
eureKARE is targeted on two rising and cutting-edge fields of analysis which have the potential to disrupt and revolutionize the life sciences business: the microbiome and artificial biology. As much as 90% of all ailments might be linked to the dysfunction and imbalance of the microbiome with the sector forecast to succeed in $1.6 billion by 2028 at a CAGR of 21%. Artificial biology, which includes gene and cell remedy and industrial purposes equivalent to information storage and bioproduction, has seen big advances lately and is predicted to have far-reaching implications on the life sciences and different industries and for sufferers. It’s forecast to succeed in $57 billion by 2028 at a CAGR of 25% per 12 months. Gene therapies alone already generate c.$4 billion revenues with big potential in gene enhancing, siRNA, mRNA, and is forecast to succeed in c.$10 billion by 2028.
Europe’s scientists are on the forefront of microbiome and artificial biology analysis as a result of modern work and thought management going down at prestigious universities and analysis facilities. eureKARE believes there’s a great alternative to industrialize this translational analysis by constructing bridges between academia and business.
Rodolphe Besserve, Chief Government Officer of eureKARE, commented: “European science stays beneath exploited in comparison with international locations just like the US, with the hole between academia and massive pharma widening over time. eureKARE goals to construct bridges between these two our bodies to create and assist new ventures. eureKARE has assembled an professional staff and, along with our top-notch Scientific Advisory Board, we need to create a novel ecosystem of ideation and cross-fertilization of experience to construct profitable firms.”
eureKARE has a two-step funding method to ship long-term worth creation constructed across the two main inflection factors in pharmaceutical growth. The Firm helps translational analysis by creating and financing new firms out of excessive worth European science by its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Artificial biology). These studios are designed to pick and nurture top quality European science and create a novel ecosystem, placing sources and experience behind scientists and ideas to create new firms. The Firm additionally intends to spend money on extra mature biotech firms (Sequence B or after) and can systematically suggest to supply some liquidity to early traders, thereby addressing a crucial want within the European biotech subject.
eureKARE will create 3-5 new ventures a 12 months and spend money on 3-5 present firms. This good mixture of early-stage ventures with excessive development potential and extra mature de-risked firms mitigates threat for shareholders.
eureKARE has a quickly rising portfolio comprising three thrilling ventures so far: Stellate Therapeutics within the gut-brain axis subject, the XNA expertise firm Omne Possibile and NovoBiome, a discovery platform devoted to the gut-liver axis.
“Every of those firms has the potential to supply disruptive options in its chosen area. These are good examples of what eureKARE needs to do. Pondering outdoors the field is in our DNA. The fast COVID-19 vaccine growth has proven the facility of human ingenuity and this mannequin can be a core inspiration for us as we progress,” added Rodolphe Besserve.
eureKARE is guided by influential founder, Alexandre Mouradian, together with a pan-European staff led by famend biotech professional Rodolphe Besserve. eureKARE’s Scientific Advisory Board consists of eight worldwide main lights of their revered information base, who will assist the corporate in all of its strategic and funding choices.
Commenting on the launch, Alexandre Mouradian, Founder & Chairman of eureKARE, mentioned: “Europe is on the forefront of microbiome and artificial biology analysis and it’s important to search out modern new funding approaches to assist the subsequent wave of life science entrepreneurs. By way of eureKARE’s pioneering method, we’re poised to establish, choose and nurture the perfect European science to create thrilling new firms with the potential to disrupt and revolutionize the life sciences business for the advantage of sufferers, whereas delivering shareholder worth.”
eureKARE is a pioneering new firm centered on financing and constructing subsequent technology biotechnology firms within the cutting-edge fields of the microbiome and artificial biology. eureKARE has a two-step funding method to ship long-term worth creation. The Firm helps translational analysis by creating and financing new firms out of excessive worth European science by its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Artificial biology). The Firm additionally intends to spend money on extra mature biotech firms and can systematically suggest to supply some liquidity to early traders, thereby addressing a crucial want within the European biotech subject. Guided by its influential founder, Alexandre Mouradian, and a pan-European staff, eureKARE has a quickly rising portfolio of firms which have the potential to disrupt the life sciences business.
eureKARE is headquartered in Luxembourg, with a presence in France & Belgium. For extra info go to: https://eurekare.eu/
NovoBiome is a drug discovery firm centered on the crucial nexus of liver, intestinal ailments and the intestine microbiome. It’s creating breakthrough Dwell Biotherapeutics Merchandise (LBPs), a novel and rising class of medication containing dwelling micro-organisms which have a constructive affect on the well being and physiology of the host. NovoBiome’s first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic situations equivalent to Non-Alcoholic Fatty Liver Illness (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). The Firm is creating an ex-vivo analysis and discovery platform, NovoSift®, designed to imitate human intestinal physiology that may unlock new insights into illness pathophysiology, novel drug targets, compounds and LBP drug candidates.
NovoBiome is headquartered in France. For extra info, please go to: www.novobiome.eu
About Omne Possibile
Omne Possibile is a pioneering, world technological chief in XNA, creating customizable constructions to outperform present DNA and RNA applied sciences. Its aim is to harness the transformative energy of XNA in areas together with healthcare, info expertise and good supplies. The Firm’s preliminary focus is on growth of XNA polymers for info storage and XNA constructing blocks for improved messenger therapeutics. Omne Possibile has R&D hubs in Leuven, Belgium, and Basel, Switzerland. It was based by main European artificial biologists and is supported by a world class scientific advisory board.
For extra info, please go to www.omnepossibile.com
About Stellate Therapeutics
Stellate Therapeutics is a non-public world biotechnology firm that develops small molecules produced by the microbiome into first-in-class therapies for neurological ailments (Parkinson and Alzheimer ailments). Stellate can be evaluating a portfolio of latest drug candidates in different situations, with capabilities throughout discovery, screening, manufacturing and diagnostic growth.
For extra info, go to www.stellate-tx.com.
Marina Shapochnik, Head Investor Relations
Consilium Strategic Communications
Amber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs
+44 (0) 203 709 5000